Health Canada approves two AstraZeneca COVID-19 vaccines
Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine and a related shot by the Serum Institute of India for use in this country with the first doses expected to arrive soon.
COVID-19 Testing: More details
COVID-19 Resources: More details
GVI Clinical Development Solutions (CDS) is an innovative contract research organization focused on quality, timeliness, and cost-effective services. The company is committed to delivering excellence in clinical development services, and is experienced in cardiovascular and metabolic disease fields.
CDS's flexibility and active participation in the critical stages of the clinical development process makes it an ideal partner for emerging life science companies, academic institutes, and public health organizations carrying out their own clinical trials. CDS is proud to say it consistently delivers.
Please visit CDS's website for more information on its clinical project management, clinical trial monitoring, clinical trial and drug safety evaluation, clinical site document management, regulatory affairs, and clinical quality assurance and data management services.
member
Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine and a related shot by the Serum Institute of India for use in this country with the first doses expected to arrive soon.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.